Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results
Background: With the increasing use of immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) have become more prevalent in oncological practice. Clinical approaches vary due to the exclusion of patients with comorbidities from trials and the lack of long-term data on irAEs. As i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | ESMO Real World Data and Digital Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949820125000360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|